# Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)

> **NCT06114940** · PHASE2 · TERMINATED · sponsor: **Jinling Hospital, China** · enrollment: 17 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06114940
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-20
- **Primary completion:** 2026-01-10
- **Final completion:** 2026-01-10
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for subjects' endpoints before and after the change.
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114940, "Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06114940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*